课题基金 / 基金详情

Project 3 - Genome-Guided Therapeutic Vulnerabilities in Esophageal Cancer

Project 3 - Genome-Guided Therapeutic Vulnerabilities in Esophageal Cancer
项目 3 - 基因组引导的食管癌治疗脆弱性
批准号:
10214546
负责人:
Adam Joel Bass
金额:
$16.7万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-08-15 至 2024-06-30

项目摘要

项目成果

Adam Joel Bass的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY – PROJECT 3 New therapies are desperately needed for esophageal cancer, which is responsible for >400,000 deaths annually. Herein we propose to build on momentum from our prior studies, founded on our observation that the most prominent genomic targets in esophageal cancer, both squamous cell carcinoma (ESSC) and adenocarcinoma (EAC), are amplifications of genes encoding mediators of the cell cycle such as CCND1=Cyclin D1 (collaboration with Project 3) and CCNE1=Cyclin E1 and genes encoding receptor tyrosine kinases such as EGFR (collaboration with Project 1) and ERBB2. Given this genomic landscape, a key premise of our work has been that developing therapeutic approaches that integrate targeting of both active kinases and cell cycle dysregulation will be remarkably beneficial. While these data, hypotheses and premises all continue to hold true, we now propose a more nuanced assessment of how cell cycle dysregulation may impact tumorigenesis and optimal cancer therapy. Specifically, we hypothesize that amplification and overexpression of Cyclin D1 and Cyclin E1 can have effects upon the tumor microenvironment and upon genomic stability, both of which have clear implications for optimal therapy. This hypothesis will be pursued through the following interrelated Specific Aims: (1) To determine how CDK4/6 inhibitors impact the tumor microenvironment in CCND1-amplified esophageal squamous cell carcinoma and to define enhanced immune therapy strategies; and (2) To elucidate how CCNE1 amplification promotes chromosomal instability, kinase amplification and immune evasion in esophageal adenocarcinoma. Together, these studies will help us develop rationale, biomarker-guided therapies for these deadly cancers. This work will be done in close collaboration with Projects 1 and 2 to drive presentations, publications and transform the clinical landscape of esophageal cancer, and to utilize the core facilities in an integrated fashion with the other Projects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Role of RHOA in Diffuse Gastric Cancer
  • 批准号:
    9904118
  • 项目类别:
  • 资助金额:
    $67.73万
  • 财政年份:
    2018
  • 负责人:
    Adam Joel Bass
  • 依托单位:
The Role of RHOA in Diffuse Gastric Cancer
In Vivo Laser Capture Microdissection
  • 批准号:
    9207464
  • 项目类别:
  • 资助金额:
    $64.74万
  • 财政年份:
    2016
  • 负责人:
    Adam Joel Bass
  • 依托单位:
Novel Roles for Oncogenic SOX2 in Esophageal Squamous Cell Carcinoma
  • 批准号:
    9307770
  • 项目类别:
  • 资助金额:
    $38.49万
  • 财政年份:
    2015
  • 负责人:
    Adam Joel Bass
  • 依托单位:
国内基金
海外基金
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
  • 批准号:
    30840003
  • 项目类别:
    专项基金项目
  • 资助金额:
    12.0万元
  • 批准年份:
    2008
  • 负责人:
    焦宇飞
  • 依托单位: